Literature DB >> 25000933

Seasonal and perennial allergic conjunctivitis.

Alex H C Wong, Stefani S N Barg, Alexander K C Leung1.   

Abstract

Seasonal and perennial allergic conjunctivitis are IgE-mediated, hypersensitivity conditions characterized by ocular pruritus, epiphora, and hyperemia. Proper diagnosis is usually made clinically based on history and physical examination. Diagnostic procedures are rarely necessary. Non-pharmacological measures, such as environmental modification and proper eye care, should be considered for all patients with allergic conjunctivitis. Pharmacological interventions may also be required. Milder cases can be treated with short-term topical ophthalmic therapy such as a decongestant/ antihistamine combination, a mast cell stabilizer, or a multi-action agent. Moderate to severe cases may require longer usage of the above agents and/or the addition of an oral antihistamine. Refractory cases may necessitate the use of topical ophthalmic corticosteroids and topical NSAIDs. Immunotherapy, whether via the subcutaneous route or the intranasal route, should be considered in the treatment of persistent severe cases refractory to conventional treatment. Despite all the available therapeutic agents, there continues to be a constant need to discover more effective ways to treat seasonal and perennial allergic conjunctivitis. This article also discusses recent patents related to the field.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25000933     DOI: 10.2174/1872213x08666140704113452

Source DB:  PubMed          Journal:  Recent Pat Inflamm Allergy Drug Discov        ISSN: 1872-213X


  8 in total

Review 1.  Prevalence of Comorbidity between Dry Eye and Allergic Conjunctivitis: A Systematic Review and Meta-Analysis.

Authors:  Yasutsugu Akasaki; Takenori Inomata; Jaemyoung Sung; Masahiro Nakamura; Koji Kitazawa; Kendrick Co Shih; Takeya Adachi; Yuichi Okumura; Kenta Fujio; Ken Nagino; Akie Midorikawa-Inomata; Mizu Kuwahara; Kunihiko Hirosawa; Tianxiang Huang; Yuki Morooka; Hurramhon Shokirova; Atsuko Eguchi; Akira Murakami
Journal:  J Clin Med       Date:  2022-06-23       Impact factor: 4.964

Review 2.  Therapeutic Targets in Allergic Conjunctivitis.

Authors:  Bisant A Labib; DeGaulle I Chigbu
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-28

3.  Effect of alcaftadine 0.25% on ocular itch associated with seasonal or perennial allergic conjunctivitis: a pooled analysis of two multicenter randomized clinical trials.

Authors:  Joseph B Ciolino; Eugene B McLaurin; Nicholas P Marsico; Stacey L Ackerman; Julia M Williams; Linda Villanueva; David A Hollander
Journal:  Clin Ophthalmol       Date:  2015-05-02

Review 4.  Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis.

Authors:  DeGaulle I Chigbu; Alissa M Coyne
Journal:  Clin Ophthalmol       Date:  2015-07-08

5.  Risk of allergic conjunctivitis in patients with type 1 diabetes mellitus: a population-based retrospective cohort study.

Authors:  Yin-Huei Chen; Cheng-Li Lin; Da-Tian Bau; Yi-Chih Hung
Journal:  BMJ Open       Date:  2017-06-19       Impact factor: 2.692

6.  The histaminergic control of the iridal vascular tone in rats and its influencing by topical administration of olopatadine and ranitidine.

Authors:  Dragoș-Constantin Luncă; Horia Păunescu; Ovidiu Mușat; Ion Fulga
Journal:  Rom J Ophthalmol       Date:  2019 Jan-Mar

7.  Comparison of cytotoxicities and anti-allergic effects of topical ocular dual-action anti-allergic agents.

Authors:  Sung Il Kim; Choul Yong Park; Gladys Fordjuor; Jong Heon Lee; Jong Soo Lee; Ji Eun Lee
Journal:  BMC Ophthalmol       Date:  2019-11-08       Impact factor: 2.209

8.  Effectiveness of a modified therapeutic protocol for the management of vernal keratoconjunctivitis based on Bonini's graded clinical severity.

Authors:  Anuradha Pradhan; Sabyasachi Pattanayak; Jayashree Dora; Praveen Subudhi
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.